JNJ
Another analyst, another notch higher
Johnson & Johnson is collecting price-target raises like it’s playing a very expensive arcade game. This time, Raymond James lifted its target to $258 from $237 and kept an Outperform rating, which points to roughly 7.9% upside from the new mark.
The Street is still leaning bullish
This isn’t a lonely call. MarketBeat’s consensus now sits at a Moderate Buy with an average target of $247.48, and the recent notes list is basically a parade of upgrades and fresh targets:
- UBS kept a buy rating in January
- Citi raised its target to $285 and stayed bullish
- Goldman Sachs lifted its target to $275
- Stifel set a $250 target
So yeah, analysts are still treating J&J like the steady adult in the room while the rest of the market flails around in a coffee-fueled panic.
Why you should care
For investors, analyst price-target hikes don’t move the business itself, but they do shape sentiment — and sentiment can matter when a mega-cap healthcare name is trying to grind higher after earnings. If the bulls are right, J&J still has room to rerate even without needing a superhero growth story.
Big picture: when a stock as massive as J&J keeps getting its ceiling raised, it usually means Wall Street sees less drama and more durability — which, in 2026, is starting to sound pretty attractive.